Vanda Pinto, PhD, science writer —

Trikafta (elexacaftor/tezacaftor/ivacaftor) improved lung function and reduced inflammation throughout the body over six months in patients with cystic fibrosis (CF), a new study reports. Treatment with the triple-combination therapy also reduced detection of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus, or MRSA, two harmful bacteria that can cause…

A single dose of 4D-710, an aerosol gene therapy candidate developed by 4D Molecular Therapeutics (4DMT) for adults with cystic fibrosis (CF), was reported to be safe and restored CFTR protein production in lung tissue samples from three patients enrolled in a Phase 1/2 clinical trial. Interim trial…

Treatment with Orkambi (lumacaftor/ivacaftor) for six months was found to improve exercise endurance in three adults with cystic fibrosis (CF), a new study showed. Moreover, by the end of the study, all three men experienced less leg discomfort and less dyspnea, or shortness of breath. For two patients,…

For the second consecutive year, Owl Cyber Defense, a provider of network cybersecurity solutions, will be a presenting sponsor in the 22nd annual Swing for Cystic Fibrosis (CF) Charity Golf Classic — a tournament held to help raise awareness and funds for CF. The event is set…

Supplemental oxygen lessened the abundance of some microbial species in sputum samples from people with cystic fibrosis (CF) while sparing others, including Pseudomonas aeruginosa and Staphylococcus aureus, the main causes of bacterial lung infections in patients, a study reported. A need for caution exists when using supplemental oxygen, “historically ……

Children with cystic fibrosis (CF) whose intestinal microbe populations — or gut microbiome — were dominated by Bifidobacteria had fewer hospitalizations and pulmonary exacerbations, needed fewer antibiotics, and showed lower inflammation in the gut than children with a gut microbiota favoring Bacteroides, a study reported. A dominance of Bifidobacteria…

Kaftrio (elexacaftor, tezacaftor, and ivacaftor) is safe and effective in children with cystic fibrosis (CF) ages 6 to 11 with specific genetic mutations and advanced lung disease, according to a small study. Findings showed the therapy improved children’s lung function and reduced the need for antibiotics. The children’s…

A $2.7 million grant from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health (NIH), has been awarded to two stem cell researchers at the University of Houston investigating an alternative cause of chronic lung inflammation in people with cystic fibrosis (CF). The project,…

A fungus called Aspergillus fumigatus can significantly affect lung function and structure, as well as increase the number of pulmonary exacerbations — episodes of a sudden worsening of respiratory symptoms — in children with cystic fibrosis (CF), a study suggests. The findings shed light on the need for early…

Home monitoring with a mobile phone-linked spirometry device may provide an effective way of detecting pulmonary exacerbations — episodes of a sudden worsening of respiratory symptoms — in people with cystic fibrosis (CF), a pilot study suggests. The findings showed more pulmonary exacerbations were identified through home monitoring…